

Freedom of Information request 57-21

Request and Response

I am researching the incidence and treatment of melanoma and breast cancer. Could you please answer the following four questions for patients treated by your trust?

1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?

<5 patients

2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:

- Cobimetinib - 0
- Dabrafenib - 0
- Dabrafenib AND Trametinib - 0
- Encorafenib AND Binimetinib - 0
- Ipilimumab - 0
- Ipilimumab AND Nivolumab - 0
- Nivolumab - <5
- Pembrolizumab - <5
- Trametinib - 0
- Vemurafenib - 0
- Vemurafenib AND Cobimetinib - 0
- Other active systemic anti-cancer therapy - 0
- Palliative care only

3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY:

- Ipilimumab - 0
- Ipilimumab AND Nivolumab - 0
- Nivolumab - <5
- Pembrolizumab - <5
- Any other therapies - 0

4. In the past 3 months how many patients were treated with the following for breast cancer?

- Abemaciclib + Anastrozole/Exemestane/Letrozole - 0
- Abemaciclib + Fulvestrant - 0
- Alpelisib + Fulvestrant - 0
- Atezolizumab - 0
- Bevacizumab - 0
- Eribulin - 0
- Everolimus + Exemestane - 0
- Fulvestrant as a single agent - 0
- Gemcitabine + Paclitaxel - 0
- Lapatinib - 0
- Neratinib - <5
- Olaparib - 0
- Palbociclib + Anastrozole/Exemestane/Letrozole - 14
- Palbociclib + Fulvestrant - <5

- Pertuzumab + Trastuzumab + Docetaxel - <5
- Ribociclib + Anastrozole/Exemestane/Letrozole - 0
- Ribociclib + Fulvestrant - 0
- Talazoparib - 0
- Transtuzumab + Paclitaxel - <5
- Transtuzumab as a single agent - 10
- Trastuzumab emtansine - <5
- Any other active systemic anti-cancer therapy - 32

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the [ISD Statistical Disclosure Control Protocol](#).

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **57-21** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.